Clinical Research Directory

Inclusion Criteria: Line 1: - Age \>18 at time of signing informed consent form * Signed informed consent form Line 2: - Primery liver tumor * Age \>18 at time of signing informed consent form * Signed informed consent form Exclusion Criteria: Line 1: - Active or history of neoplastic malignancy * Active autoimmune disease ongoing treatment with immunosuppressive therapy * Evidence of positive HIV, HCV, HBV test * Diabetes * Failure to sign informed consent form Line 2: - Concomitant diseases with life expectancy of less than 12 months * Chronic autoimmune or inflammatory diseases * Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies * Other extrahepatic neoplasms occurring or in the last 3 years except for tumors resected with curative intent and without evidence of relapse for \>3 years prior to signing informed consent and considered low risk of relapse * HIV infection * Failure to sign informed consent form